Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX, Apatinib Plus Sintilimab for Metastatic ICC
NCT04682249Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and Rivoceranib in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 6 months. Planned start Dec 2020; status: withdrawn.
02
Drugs
sintilimabRivoceranib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04682249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682249.